Alloy LegitScript and Accreditation Status: Is Alloy a Legitimate Menopause Telehealth Service?

What Is LegitScript, and Why Does It Matter for Telehealth?

LegitScript is an independent certification body that verifies whether online pharmacies and telehealth platforms comply with applicable laws and professional standards. Google, Meta, and several major payment processors require LegitScript certification before allowing healthcare advertisers to run ads for prescription products. A platform without certification is not automatically illegal, but the absence does remove one layer of independent vetting.

How LegitScript Certification Works

LegitScript reviews a platform's prescribing practices, pharmacy partners, drug sourcing, and state licensing before granting certification. Certified pharmacies must hold a valid license in every state where they dispense, follow the FDA's current good manufacturing practice (cGMP) standards, and dispense only FDA-approved or legally compounded drugs. The FDA's guidance on compounded drug products outlines the legal boundaries separating 503A compounding pharmacies (patient-specific) from 503B outsourcing facilities (larger-scale). [1]

Alloy's Current Certification Status

Alloy Women's Health does not appear in the LegitScript certified telehealth or certified pharmacy databases as of January 2025. This does not constitute an FDA violation on its own, but it does mean the platform has not submitted to the external audit that certification requires. Patients relying on LegitScript status as a proxy for safety should note this gap.

What Regulators Actually Enforce

State medical boards license the individual physicians who write prescriptions through Alloy. The Federation of State Medical Boards (FSMB) has published explicit standards for telemedicine practice, requiring a valid physician-patient relationship, documented informed consent, and follow-up care protocols. [2] Alloy's model involves an intake questionnaire and a clinician review, which can satisfy these requirements, but the depth of that clinical interaction varies by state law.

Is Alloy a Legitimate Medical Service?

Alloy is a legally operating telehealth business. Its prescribing physicians hold state licenses, the platform uses real FDA-approved medications for many of its offerings, and its clinical focus on menopause HRT is grounded in well-established evidence. None of that is in dispute. The legitimacy question is more nuanced: does the platform meet the same standards as an accredited outpatient clinic or a URAC-accredited telepharmacy?

FDA-Approved vs. Compounded Medications

Alloy prescribes both FDA-approved hormone products (such as estradiol patches and oral micronized progesterone) and compounded hormone preparations. FDA-approved products have undergone rigorous efficacy and safety review. Compounded bioidentical hormones, which are frequently promoted as equivalent, have not passed that same review process. The FDA has stated explicitly that compounded hormones are not FDA-approved and that claims of superiority over approved products lack evidence. [3]

The North American Menopause Society's 2022 position statement on hormone therapy notes that "FDA-approved hormone therapies remain the standard of care," and distinguishes these from custom-compounded preparations, which carry additional uncertainty around dose consistency. [4]

Clinical Protocol and Guideline Alignment

The NAMS 2023 menopause hormone therapy position statement supports initiating systemic estrogen therapy for bothersome vasomotor symptoms in women under 60 or within 10 years of menopause onset, absent contraindications. [5] Alloy's public treatment descriptions broadly follow this framework, recommending estradiol with progesterone for women with an intact uterus, which aligns with standard practice to reduce endometrial cancer risk. [6]

The Women's Health Initiative (WHI), the largest randomized controlled trial of postmenopausal hormone therapy (N=27,347 across both arms), found that the risk-benefit profile of HRT depends heavily on formulation, route of administration, and timing of initiation. [7] A platform that applies the same protocol to every patient without accounting for these variables falls short of what the WHI evidence actually supports. Alloy's intake process should be evaluated against this standard.

Prescriber Accountability

Legitimate telehealth requires that a licensed physician (or mid-level practitioner operating within their scope) reviews each patient's history, assesses contraindications, and takes responsibility for the prescription. Alloy states that board-certified physicians review patient submissions. Patients should ask directly for the prescribing clinician's name and verify their license through their state medical board's public lookup tool before filling any prescription.

Alloy Complaints and Consumer Feedback

Consumer complaint data provides a practical signal about service quality that clinical guideline compliance alone cannot capture.

BBB Profile and Complaint Themes

The Better Business Bureau (BBB) profile for Alloy Women's Health shows a history of consumer complaints, with recurring themes around subscription cancellation difficulty, delayed shipping of medications, and challenges reaching customer support. The BBB accreditation status and rating of any telehealth company can change; patients should check the current BBB profile directly at bbb.org before subscribing.

Complaint patterns of this type are common across D2C telehealth models. They reflect business-practice concerns rather than clinical safety failures, but they do affect the overall patient experience.

FDA MedWatch and Adverse Event Reporting

Patients who experience adverse effects from any medication, whether dispensed through Alloy or another platform, can report to FDA MedWatch. [8] The FDA's database of adverse event reports (FAERS) allows the public to search for reported events associated with specific drugs. For estradiol products, the FDA's prescribing information for transdermal estradiol patches details known risks including venous thromboembolism, stroke, and breast cancer with prolonged combined use. [9]

State Attorney General Actions

No state attorney general enforcement action against Alloy was identified in publicly available records as of the publication date of this article. That status can change. The FDA's database of warning letters is searchable and represents the most authoritative record of federal regulatory action against any pharmacy or healthcare company. [10]

Hormone Therapy Evidence Base: What the Trials Actually Show

Evaluating any HRT platform requires understanding what the underlying science supports, because marketing language sometimes outruns the data.

Vasomotor Symptom Relief

The REPLENISH trial (N=1,835), a randomized, double-blind, Phase 3 study, found that the combination oral product TX-001HR (17-beta estradiol 1 mg with progesterone 100 mg) reduced mean moderate-to-severe vasomotor symptom frequency by 74% at week 12 compared to 51% for placebo (P<0.001). [11] This is the kind of evidence supporting FDA-approved oral combination HRT. Compounded alternatives do not have equivalent trial data.

Cardiovascular and Breast Cancer Risk

The WHI estrogen-plus-progestin arm (N=16,608) reported a hazard ratio of 1.26 for invasive breast cancer with conjugated equine estrogen plus medroxyprogesterone acetate after a mean 5.6 years of follow-up. [7] Critically, transdermal estradiol combined with micronized progesterone carries a different risk profile. The E3N cohort study (N=80,377 French women) found no statistically significant increase in breast cancer risk for transdermal estradiol plus progesterone (relative risk 1.00, 95% CI 0.83 to 1.22). [12] Route of administration matters, and a legitimate prescriber should discuss this difference.

Timing and the "Window of Opportunity"

The Kronos Early Estrogen Prevention Study (KEEPS, N=727) examined HRT initiated within 3 years of menopause onset and found no significant progression of carotid intima-media thickness or coronary artery calcium compared to placebo over 4 years. [13] This supports the timing hypothesis endorsed by NAMS: earlier initiation in healthy, recently menopausal women carries a more favorable cardiovascular risk profile than later initiation. Alloy's intake process should capture time since menopause to apply this distinction appropriately.

Bone Density Benefits

A Cochrane systematic review of hormone therapy for preventing osteoporosis (17 trials, N=4,876) found that HRT significantly reduced vertebral fracture risk (RR 0.66, 95% CI 0.49 to 0.89) and non-vertebral fractures (RR 0.87, 95% CI 0.76 to 1.00) compared to placebo. [14] The U.S. Preventive Services Task Force does not currently recommend HRT solely for fracture prevention in postmenopausal women due to the overall risk-benefit balance, but the bone data remain clinically relevant for patients already choosing HRT for symptom management. [15]

Compounding Pharmacies: The Regulatory Gray Area

Many D2C menopause platforms, including Alloy, route some prescriptions through 503A compounding pharmacies. Understanding the regulatory framework here protects patients.

503A vs. 503B: What the Difference Means

A 503A pharmacy compounds drugs for individual patients based on a valid prescription. It is regulated primarily by state boards of pharmacy, not the FDA, unless it violates specific federal statutes. A 503B outsourcing facility is voluntarily registered with the FDA and subject to cGMP inspections, making its products more analogous to manufactured drugs. [1] Alloy's compounding pharmacy partners should be identifiable by patients; patients have the right to ask which specific pharmacy will fill their prescription and to verify that pharmacy's state license.

PCAB Accreditation

The Pharmacy Compounding Accreditation Board (PCAB), administered through URAC, offers voluntary accreditation for compounding pharmacies that meet specific quality standards. A pharmacy holding PCAB accreditation has undergone third-party review of its sterile and non-sterile compounding practices. Patients using any compounded HRT product should ask whether their dispensing pharmacy carries PCAB accreditation.

Hormone Dose Consistency in Compounded Products

The FDA has documented concerns about dose variability in compounded hormone preparations. A study published in Menopause (2020) tested 34 compounded progesterone preparations and found that 67% fell outside the 90-110% potency range considered acceptable for FDA-approved drugs. [16] This variability has direct clinical implications: a patient receiving 67% of the intended progesterone dose may have inadequate endometrial protection.

Telehealth Regulatory Compliance: What Patients Should Verify

Before using Alloy or any D2C HRT platform, patients benefit from checking several specific items.

Physician Licensure Verification

Every prescribing physician should hold an active, unrestricted license in the patient's state. State medical board license lookup tools are free and publicly accessible. The FSMB maintains a directory of state board websites. [2] A prescription written by an out-of-state physician without a valid in-state license is legally questionable and potentially unenforceable by a pharmacy.

Pharmacy License and Inspection History

The dispensing pharmacy should hold an active license in the state where it is located and, for interstate shipments, in the state where the patient resides. The National Association of Boards of Pharmacy (NABP) maintains a list of pharmacies that have received a "not recommended" designation, which covers operations that do not meet safety standards. [17]

Informed Consent Documentation

A compliant telehealth visit should include written informed consent covering the risks of the prescribed therapy, alternatives, and the limitations of a remote consultation. The American College of Obstetricians and Gynecologists (ACOG) has published guidance on telehealth in obstetrics and gynecology specifying that informed consent standards in telehealth should match those of in-person care. [18]

Follow-up and Monitoring Requirements

NAMS guidelines recommend that women on systemic HRT receive follow-up within 3 to 6 months of initiation to assess symptom control, side effects, and any emerging contraindications. [5] A platform that writes a prescription and then has no structured follow-up pathway does not meet this standard. Patients should ask explicitly about Alloy's follow-up protocol before subscribing.

How Alloy Compares to Accreditation Benchmarks

No single accreditation body governs all telehealth platforms. The relevant standards come from multiple sources.

URAC Telehealth Accreditation

URAC offers telehealth accreditation covering clinical quality, patient safety, and business practices. URAC-accredited organizations have demonstrated compliance with standards covering credentialing, utilization management, and quality improvement. Alloy does not currently hold URAC telehealth accreditation based on publicly available information as of January 2025.

Joint Commission Certification

The Joint Commission certifies healthcare organizations for quality and patient safety. Its telehealth certification program evaluates clinical operations, credentialing, and performance improvement. Alloy does not appear in the Joint Commission's online certificate verification system as of the publication date of this article.

What Accreditation Absence Means in Practice

Absence of voluntary accreditation does not make a service illegal or dangerous. Most small D2C telehealth startups lack these credentials. The practical implication is that patients cannot rely on independent third-party audits of Alloy's clinical processes. The burden of due diligence falls on the patient and, where possible, on the patient's primary care physician or gynecologist who can review any prescribed regimen.

The Endocrine Society's clinical practice guideline on menopausal hormone therapy recommends that treatment decisions be individualized based on a woman's specific symptom burden, cardiovascular risk, family history of breast cancer, and personal preferences. [19] A streamlined D2C intake form may not capture all of these variables with sufficient granularity.

Red Flags and Green Flags: A Clinical Checklist

Patients evaluating Alloy or any D2C HRT platform should look for specific signals.

Green Flags

A platform earns confidence by providing the prescribing physician's name and license number upfront, naming the dispensing pharmacy before checkout, offering structured follow-up at 3 and 6 months, prescribing FDA-approved formulations as the first-line option, and documenting a contraindication screening that covers personal and family history of breast cancer, clotting disorders, and cardiovascular disease.

Red Flags

Concern is warranted when a platform cannot identify who will prescribe or fill the prescription, defaults to compounded hormones without explaining why an FDA-approved product is unsuitable, charges a recurring subscription before a physician has reviewed the intake, or provides no mechanism for reporting adverse effects.

The FDA's guidance on buying medicines online states that patients should only fill prescriptions from licensed pharmacies that require a valid prescription from a licensed healthcare provider. [20] This is the minimum legal bar; accreditation and LegitScript certification represent higher, voluntary standards above that bar.